| Entry |
|
|---|
| Name |
Amplified MET to RAS-ERK signaling pathway
|
|---|
| Definition |
MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK |
|---|
| Expanded |
4233v3 -> 2885 -> (6654,6655) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595) |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
|
|---|
| Gene |
| 4233 | MET; MET proto-oncogene, receptor tyrosine kinase |
| 2885 | GRB2; growth factor receptor bound protein 2 |
| 6654 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 |
| 6655 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 |
| 3265 | HRAS; HRas proto-oncogene, GTPase |
| 3845 | KRAS; KRAS proto-oncogene, GTPase |
| 4893 | NRAS; NRAS proto-oncogene, GTPase |
| 369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
| 673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
| 5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
| 5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
| 5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
| 5594 | MAPK1; mitogen-activated protein kinase 1 |
| 5595 | MAPK3; mitogen-activated protein kinase 3 |
|
|---|
| Variant |
4233v3 (MET*) MET amplification
|
|---|
| Reference |
|
|---|
| Authors |
Appleman LJ |
|---|
| Title |
MET signaling pathway: a rational target for cancer therapy. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Feng Y, Ma PC |
|---|
| Title |
Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Kawakami H, Okamoto I |
|---|
| Title |
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
